News | Peptide Advocate

Latest NewsThe 5 Most Common GLP-1 Side Effects (and How to Beat Them)Read Article

News/ Peptide AdvocateOctober 30, 2026

The 5 Most Common GLP-1 Side Effects (and How to Beat Them)

Nausea, diarrhea, constipation, vomiting, and indigestion are the most common GLP-1 side effects. They usually show up early, stay mild, and fade with time. Learn what to expect on Zepbound (tirzepatide) and Wegovy (semaglutide), and the simple fixes that help most people stay on track.

Peptide Advocate

November 1, 2026

The New HHS Peptide Policy: What It Means for BPC-157, TB-500 and Four More

HHS now lets licensed pharmacies compound six peptides, including BPC-157 and TB-500, under strict rules. What changed, what didn't, and how to comment.

Read Article

Peptide Advocate

October 28, 2026

Beyond Tirzepatide: The New Weight-Loss Peptides Racing Toward FDA Approval

Retatrutide, amylin peptides, a monthly shot and more: where every new weight-loss peptide stands with the FDA, and how each compares with tirzepatide.

Read Article

Peptide Advocate

October 28, 2026

Hit a Plateau on Tirzepatide? Why Weight Loss Stalls and What Actually Helps

Weight loss on tirzepatide almost always slows down. Here's what the trials show about why plateaus happen and the evidence-backed ways to respond.

Read Article

Peptide Advocate

October 22, 2026

GHK-Cu: What the Science Really Says About the “Copper Peptide”

GHK-Cu is a natural copper peptide that’s been in skin care for years, and now people are injecting it. Here’s what the research shows for creams compared with injections, what’s known about safety, and where GHK-Cu stands with the FDA.

Read Article

Peptide Advocate

October 22, 2026

The GLOW Blend: What the Science Really Says About the “Glow” Peptide Stack

GLOW pairs GHK-Cu, a copper peptide with a long skin-care history, with BPC-157 and TB-500. Here’s what the science shows, why injecting copper peptide isn’t the same as using a cream, and where GLOW stands with the FDA.

Read Article

Peptide Advocate

October 22, 2026

The KLOW Blend: What the Science Really Says About This Four-Peptide Mix

KLOW mixes GHK-Cu, KPV, BPC-157 and TB-500 into one injectable vial. Each ingredient has an interesting research story, but the blend has never been tested, and two ingredients are banned in sport. Here’s what’s known and where it stands with the FDA.

Read Article

Peptide Advocate

October 20, 2026

Mazdutide: What the Science Really Says About the Two-Hormone Weight-Loss Shot

Mazdutide is a weekly injection from Eli Lilly that copies two hormones at once: GLP-1 and glucagon. It’s approved in China and has produced strong weight loss and dramatic drops in liver fat in large trials. Here’s what the research shows, what’s known about safety, and where it stands in the U.S.

Read Article

Peptide Advocate

October 16, 2026

Kisspeptin-10: What the Science Really Says About the “Hormone Master Switch”

Kisspeptin is the hormone that switches on puberty and keeps the reproductive system running, and kisspeptin-10 is its smallest active piece. Here’s what studies show for fertility, low sex drive and testosterone, what’s known about safety, and why it’s still on the FDA’s restricted list.

Read Article

Peptide Advocate

October 16, 2026

Elamipretide (SS-31): What the Science Really Says About the “Mitochondria Peptide”

In 2025, elamipretide became the first FDA-approved treatment for Barth syndrome, a rare inherited disease. Here’s how this mitochondria-targeting peptide works, what its trials in other conditions found, what’s known about safety, and why “SS-31” sold online isn’t the same as the approved drug.

Read Article

Peptide Advocate

October 16, 2026

Thymosin Alpha-1: What the Science Really Says About the “Immune Peptide”

Thymosin alpha-1 is an immune peptide made naturally in the thymus, and it’s an approved medicine in dozens of countries, but not the U.S. Here’s what the research shows, including a large sepsis trial that changed the picture, what’s known about safety, and where it stands with the FDA.

Read Article

Page 1 / 3